Search Results - "Antineoplastic Combined Chemotherapy Protocols/administration & dosage"
-
1
Authors: et al.
Contributors: et al.
Source: Acta Oncologica, Vol 64 (2025)
Acta oncologica
ACTA ONCOLOGICASubject Terms: Male, Immune Checkpoint Inhibitors/administration & dosage, Radiology, Nuclear Medicine and Imaging, Time Factors, Oncologie, THERAPY, Carcinoma, Renal Cell/secondary, immune checkpoint inhibitors, Antineoplastic Combined Chemotherapy Protocols, Medicine and Health Sciences, Ipilimumab/administration & dosage, Human health sciences, Kidney Neoplasms/mortality, Immune Checkpoint Inhibitors, RC254-282, Aged, 80 and over, OUTCOMES, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Carcinoma, Renal Cell/pathology, Hematology, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Middle Aged, Kidney Neoplasms, Progression-Free Survival, Renal cell carcinoma, Nivolumab/administration & dosage, treatment discontinuation, Carcinoma, Renal Cell/mortality, Kidney Neoplasms/drug therapy, Nivolumab, optimal treatment duration, Oncology, Female, Life Sciences & Biomedicine, Adult, DISCONTINUATION, Sciences de la santé humaine, Kidney Neoplasms/pathology, Immune Checkpoint Inhibitors/adverse effects, 3211 Oncology and carcinogenesis, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, Carcinoma, Renal Cell, Retrospective Studies, Aged, Science & Technology, Duration of Therapy, Immune Checkpoint Inhibitors/therapeutic use, Ipilimumab, MELANOMA PATIENTS, Carcinoma, Renal Cell/drug therapy, Human medicine, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Follow-Up Studies
File Description: application/pdf
Access URL: https://doaj.org/article/f0b66be9934249d38e034df42f696b62
https://hdl.handle.net/2268/335276
https://doi.org/10.2340/1651-226X.2025.43876
https://repository.uantwerpen.be/docstore/d:irua:30312
https://hdl.handle.net/10067/2161490151162165141
http://hdl.handle.net/1942/46632
http://hdl.handle.net/1854/LU-01K3QQRTE94KZYP1CX1X0WZ5CD
https://biblio.ugent.be/publication/01K3QQRTE94KZYP1CX1X0WZ5CD/file/01K42SV66F3YD38FGWT899GJ86
https://biblio.ugent.be/publication/01K3QQRTE94KZYP1CX1X0WZ5CD
http://doi.org/10.2340/1651-226x.2025.43876 -
2
Authors: et al.
Source: N Engl J Med
Elez, E, BREAKWATER Trial Investigators & Poulsen, L Ø 2025, 'Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer', The New England Journal of Medicine, vol. 392, no. 24, pp. 2425-2437. https://doi.org/10.1056/NEJMoa2501912Subject Terms: Adult, Male, Organoplatinum Compounds, Leucovorin, Cetuximab/adverse effects, Article, Young Adult, Carbamates/administration & dosage, Neoplasm Metastasis/drug therapy, Humans, Proto-Oncogene Proteins B-raf/antagonists & inhibitors, Treatments in Oncology, Aged, Aged, 80 and over, Sulfonamides/administration & dosage, Gastroenterology, Colorectal Neoplasms/drug therapy, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Middle Aged, Hematology/Oncology, Progression-Free Survival, Treatment Outcome, Mutation, Female, Fluorouracil, Gastrointestinal Tract Cancer
-
3
Authors: et al.
Source: New England Journal of Medicine
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Institut de Recerca Germans Trias i Pujol (IGTP)Subject Terms: Adult, Aged, 80 and over, Male, Gastroenterology, Colorectal Neoplasms/drug therapy, Kaplan-Meier Estimate, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Middle Aged, Hematology/Oncology, DNA Mismatch Repair, Ipilimumab, Progression-Free Survival, Nivolumab/administration & dosage, Young Adult, Nivolumab, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Humans, Female, Microsatellite Instability, Ipilimumab/administration & dosage, Colorectal Neoplasms, Gastrointestinal Tract Cancer, Treatments in Oncology, Aged
-
4
Authors: et al.
Contributors: et al.
Source: Blood, Vol. 143, no.23, p. 2363-2372 (2024)
Subject Terms: Male, Adult, Adolescent, Cytarabine / therapeutic use, Fusion Proteins, bcr-abl / genetics, Fusion Proteins, bcr-abl, Young Adult, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, Antineoplastic Combined Chemotherapy Protocols / adverse effects, Pyrimidines / therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Humans, Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy, Cytarabine, Hematopoietic Stem Cell Transplantation, Antineoplastic Combined Chemotherapy Protocols / administration & dosage, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Pyrimidines / administration & dosage, 3. Good health, Cytarabine / administration & dosage, Pyrimidines, Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy, Female, Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
File Description: application/pdf
-
5
Authors: et al.
Contributors: et al.
Source: The lancet. Healthy longevity, vol. 5, no. 6, pp. e392-e405
Subject Terms: Male, Aged, 80 and over, Squamous Cell Carcinoma of Head and Neck, Cetuximab, [SDV.CAN]Life Sciences [q-bio]/Cancer, Humans, Aged, Female, Squamous Cell Carcinoma of Head and Neck/drug therapy, Squamous Cell Carcinoma of Head and Neck/pathology, Head and Neck Neoplasms/drug therapy, Head and Neck Neoplasms/pathology, Neoplasm Recurrence, Local/drug therapy, Neoplasm Recurrence, Local/pathology, Fluorouracil/administration & dosage, Fluorouracil/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Carboplatin/administration & dosage, Carboplatin/therapeutic use, Carboplatin/adverse effects, Cetuximab/administration & dosage, Cetuximab/therapeutic use, Cetuximab/adverse effects, Carboplatin, 3. Good health, [SDV.CAN] Life Sciences [q-bio]/Cancer, Head and Neck Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Fluorouracil, Neoplasm Recurrence, Local
File Description: application/pdf
Access URL: https://pubmed.ncbi.nlm.nih.gov/38759667
https://u-picardie.hal.science/hal-04578230v1
https://doi.org/10.1016/s2666-7568(24)00048-5
https://u-picardie.hal.science/hal-04578230v1/document
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_FC7E3ACA49E02
https://serval.unil.ch/notice/serval:BIB_FC7E3ACA49E0
https://serval.unil.ch/resource/serval:BIB_FC7E3ACA49E0.P001/REF.pdf -
6
Authors: et al.
Contributors: et al.
Source: Clinical colorectal cancer, vol. 24, no. 1, pp. 82-88.e1
Subject Terms: Humans, Capecitabine/administration & dosage, Capecitabine/adverse effects, Male, Pyridines/administration & dosage, Pyridines/adverse effects, Female, Middle Aged, Rectal Neoplasms/therapy, Rectal Neoplasms/pathology, Rectal Neoplasms/mortality, Phenylurea Compounds/administration & dosage, Phenylurea Compounds/adverse effects, Aged, Neoadjuvant Therapy/methods, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Adult, Chemoradiotherapy/methods, Neoadjuvant chemoradiation, Pathological response, Phase I, Toxicity, Tyrosine kinase inhibitors (TKI)
File Description: application/pdf
Relation: info:eu-repo/semantics/altIdentifier/pmid/39537446; info:eu-repo/semantics/altIdentifier/eissn/1938-0674; info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_A4FE1C2C87680; https://serval.unil.ch/notice/serval:BIB_A4FE1C2C8768; https://serval.unil.ch/resource/serval:BIB_A4FE1C2C8768.P001/REF.pdf
-
7
Authors: et al.
Contributors: et al.
Source: Ann Surg Oncol
on behalf of the Scientific Committee of the European-African Hepato-Pancreato-Biliary Association 2022, 'Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer : An International Multicenter Cohort Study', Annals of Surgical Oncology. https://doi.org/10.1245/s10434-022-12387-2
ANNALS OF SURGICAL ONCOLOGYSubject Terms: Complications, Surgery, anesthesiology, intensive care, radiology, Leucovorin, Folfrinox, BRPC, LAPC, OS, 03 medical and health sciences, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Pancreatic Neoplasms/drug therapy, Antineoplastic Combined Chemotherapy Protocols, Medicine and Health Sciences, Humans, Retrospective Studies, Kirurgi, Neoadjuvant Therapy/adverse effects, Pancreatic Tumors, Definition, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Classification, Gemcitabine, Neoadjuvant Therapy, 3. Good health, Pancreatic Neoplasms, Fluorouracil/administration & dosage, Leucovorin/administration & dosage, Surgery, Fluorouracil
File Description: application/pdf
Access URL: https://pubmed.ncbi.nlm.nih.gov/36539580
https://research.vumc.nl/en/publications/42c5c893-43e6-4549-919c-beea33f9477b
http://hdl.handle.net/10138/355703
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-237748
https://biblio.ugent.be/publication/01GV5WDX11WX2YGFRBGRAXE46B/file/01GV5WN51S9KR9STR8QV2GFHZD
https://biblio.ugent.be/publication/01GV5WDX11WX2YGFRBGRAXE46B
http://hdl.handle.net/1854/LU-01GV5WDX11WX2YGFRBGRAXE46B
http://doi.org/10.1245/s10434-022-12387-2 -
8
Authors: et al.
Contributors: et al.
Source: Sonneveld, P, Dimopoulos, M A, Beksac, M, van der Holt, B, Aquino, S, Ludwig, H, Zweegman, S, Zander, T, Zamagni, E, Wester, R, Hajek, R, Pantani, L, Dozza, L, Gay, F, Cafro, A, De Rosa, L, Morelli, A, Gregersen, H, Gulbrandsen, N, Cornelisse, P, Troia, R, Oliva, S, van de Velden, V, Wu, K, Ypma, P F, Bos, G, Levin, M-D, Pour, L, Driessen, C, Broijl, A, Croockewit, A, Minnema, M C, Waage, A, Hveding, C, van de Donk, N W C J, Offidani, M, Palumbo, G A, Spencer, A, Boccadoro, M & Cavo, M 2021, 'Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma', Journal of Clinical Oncology, vol. 39, no. 32, JCO2101045, pp. 3613-3622. https://doi.org/10.1200/JCO.21.01045
Sonneveld, P, Dimopoulos, M A, Beksac, M, van der Holt, B, Aquino, S, Ludwig, H, Zweegman, S, Zander, T, Zamagni, E, Wester, R, Hajek, R, Pantani, L, Dozza, L, Gay, F, Cafro, A M, De Rosa, L, Morelli, A, Gregersen, H, Gulbrandsen, N, Cornelisse, P, Troia, R, Oliva, S, van de Velden, V, Wu, K L, Ypma, P F, Bos, G, Levin, M D, Pour, L, Driessen, C, Broijl, A, Croockewit, A, Minnema, M C, Waage, A, Hveding, C, van de Donk, N W C J, Offidani, M, Palumbo, G A, Spencer, A, Boccadoro, M & Cavo, M 2021, 'Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 39, no. 32, pp. 3613-3622. https://doi.org/10.1200/JCO.21.01045
Journal of Clinical Oncology, 39, 32, pp. 3613-3622Subject Terms: Dexamethasone/administration & dosage, Adult, Cancer Research, Neoplasm, Residual, Time Factors, Adolescent, Multiple Myeloma/drug therapy, BORTEZOMIB, THERAPY, Dexamethasone, Maintenance Chemotherapy, Bortezomib, Young Adult, 03 medical and health sciences, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Antineoplastic Combined Chemotherapy Protocols, Aged, Consolidation Chemotherapy, Europe, Humans, Lenalidomide, Middle Aged, Multiple Myeloma, Neoplasm Staging, Progression-Free Survival, Journal Article, IMPROVES, Lenalidomide/administration & dosage, Haematology - Radboud University Medical Center, OUTCOMES, INDUCTION, Radboudumc 9: Rare cancers RIHS: Radboud Institute for Health Sciences, STEM-CELL TRANSPLANTATION, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, OPEN-LABEL, DEXAMETHASONE, 3. Good health, LENALIDOMIDE MAINTENANCE, Oncology, Residual, Bortezomib/administration & dosage, Neoplasm, CONSENSUS
File Description: application/pdf
Access URL: https://pubmed.ncbi.nlm.nih.gov/34520219
https://vbn.aau.dk/da/publications/08b3c19a-b139-4a09-a39d-338395e3bb43
https://doi.org/10.1200/JCO.21.01045
http://www.scopus.com/inward/record.url?scp=85121950254&partnerID=8YFLogxK
https://pure.eur.nl/en/publications/3dfde1eb-dc8f-4f18-8ada-67fc665a5537
https://doi.org/10.1200/JCO.21.01045
https://vbn.aau.dk/en/publications/consolidation-and-maintenance-in-newly-diagnosed-multiple-myeloma
https://ascopubs.org/doi/10.1200/JCO.21.01045
https://www.ncbi.nlm.nih.gov/pubmed/34520219
https://iris.unito.it/handle/2318/1804086
https://research.vumc.nl/en/publications/2b32098e-ca08-476c-9883-09664c6f97bc
https://dspace.library.uu.nl/handle/1874/443724
https://pure.amsterdamumc.nl/en/publications/638bf48e-f486-4bc3-869d-1d113670cd58
https://doi.org/10.1200/JCO.21.01045
https://repository.ubn.ru.nl//bitstream/handle/2066/243943/243943.pdf
https://hdl.handle.net/2066/243943
https://hdl.handle.net/11585/865177
https://doi.org/10.1200/JCO.21.01045 -
9
Authors: et al.
Contributors: et al.
Source: RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
instnameSubject Terms: Prostatic Neoplasms / pathology, Thiohydantoins / administration & dosage, Male, 0301 basic medicine, Prostatic Neoplasms / complications, Fatigue / diagnosis, Abiraterone Acetate, Severity of Illness Index, prostatic neoplasms, Chemotherapy-Naive Patients, neoplasm metastasis, 0302 clinical medicine, Pain Measurement / statistics & numerical data, Cancer Pain / diagnosis, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Fatigue / drug therapy, apalutamide, Fatigue, Quality of Life, Pain Measurement, Fatigue / psychology, Aged, 80 and over, Patient, Double-blind, Men, Cancer Pain, Middle Aged, Progression-Free Survival, Abiraterone acetate, 3. Good health, Chemotherapy-naive patients, Thiohydantoins, Double-Blind, Adult, 03 medical and health sciences, Cancer Pain / etiology, Prostatic Neoplasms / mortality, Prostatic Neoplasms / drug therapy, Humans, Patient Reported Outcome Measures, Antineoplastic Combined Chemotherapy Protocols / administration & dosage, Cancer Pain / drug therapy, Aged, Clinical Deterioration, Prostatic Neoplasms, Androgen Antagonists, Cancer Pain / psychology, Fatigue / etiology, quality of life, Prednisone, Androgen Antagonists / administration & dosage, Follow-Up Studies
File Description: application/pdf
Access URL: https://www.auajournals.org/doi/pdf/10.1097/JU.0000000000001841
https://pubmed.ncbi.nlm.nih.gov/34039013
https://hdl.handle.net/10668/25041
https://www.ncbi.nlm.nih.gov/pubmed/34039013
https://europepmc.org/article/MED/34039013
https://lup.lub.lu.se/search/publication/d9b45cb0-ee40-4ad0-a9a7-d7ec23e9fa17
https://www.auajournals.org/doi/10.1097/JU.0000000000001841
https://pubmed.ncbi.nlm.nih.gov/34039013/
https://portal.research.lu.se/en/publications/apalutamide-plus-androgen-deprivation-therapy-for-metastatic-cast -
10
Authors: et al.
Contributors: et al.
Source: British Journal of Cancer. 125:679-686
Subject Terms: Adult, Breast Neoplasms / drug therapy, Antineoplastic Agents, Hormonal, Aminopyridines / adverse effects, Receptor, ErbB-2, Aminopyridines, Antineoplastic Agents, Breast Neoplasms, Breast Neoplasms / metabolism, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Antineoplastic Combined Chemotherapy Protocols / adverse effects, Receptors, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Hormonal / adverse effects, Humans, Purines / administration & dosage, Antineoplastic Combined Chemotherapy Protocols / administration & dosage, Estrogen / metabolism, Aged, Aged, 80 and over, Drug Tapering, Purines / adverse effects, Middle Aged, Aminopyridines / administration & dosage, ErbB-2 / metabolism, 3. Good health, Hormonal / administration & dosage, Treatment Outcome, Receptors, Estrogen, Purines, Female, Progesterone / metabolism, Receptors, Progesterone, Receptor
Access URL: https://pubmed.ncbi.nlm.nih.gov/34158598
https://www.nature.com/articles/s41416-021-01415-9
https://www.ncbi.nlm.nih.gov/pubmed/34158598
https://www.nature.com/articles/s41416-021-01415-9.pdf
https://mdanderson.elsevierpure.com/en/publications/safety-and-impact-of-dose-reductions-on-efficacy-in-the-randomise
https://snucm.elsevierpure.com/en/publications/safety-and-impact-of-dose-reductions-on-efficacy-in-the-randomise
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405616 -
11
Authors: et al.
Source: Blood
Blood, 137 (20Subject Terms: Male, Diffuse/drug therapy, Lymphoma, DNA Repair, Humanized/therapeutic use, Neoplasm/biosynthesis, Cyclophosphamide/administration & dosage, Prednisone/administration & dosage, Neoplasm Proteins/genetics, Immunologie, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Vincristine/administration & dosage, Gene Regulatory Networks, Prospective Studies, Chronic, Aged, 80 and over, Leukemia, Neoplastic/genetics, Syndrome, Sciences bio-médicales et agricoles, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Middle Aged, Combined Modality Therapy, Lymphocytic, 3. Good health, Gene Expression Regulation, Neoplastic, Disease Progression, Female, Lymphoma, Large B-Cell, Diffuse, Biochimie, 106013 Genetics, Clone Cells/pathology, Antibodies, Monoclonal, Humanized, Antibodies, Clonal Evolution, Large B-Cell, Humans, 106013 Genetik, Cyclophosphamide, Aged, Whole Genome Sequencing, Base Sequence, Doxorubicin/administration & dosage, Leukemia, Lymphocytic, Chronic, B-Cell, Clone Cells, Gene Expression Regulation, Genes, Clonal Evolution/genetics, Doxorubicin, Mutation, Neoplasm, RNA, Biologie cellulaire, B-Cell/genetics, Transcriptome, Hématologie, Genes, Neoplasm
File Description: 2 full-text file(s): application/pdf; application/pdf; 2 full-text file(s): application/vnd.openxmlformats-officedocument.wordprocessingml.document; application/vnd.openxmlformats-officedocument.wordprocessingml.document
Access URL: https://ashpublications.org/blood/article-pdf/137/20/2800/1807536/bloodbld2020005650.pdf
https://pubmed.ncbi.nlm.nih.gov/33206936
https://ucrisportal.univie.ac.at/de/publications/406d7869-f4ee-46c7-8d76-a01ef14da7d4
https://doi.org/10.1182/blood.2020005650
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163497
https://www.ncbi.nlm.nih.gov/pubmed/33206936
https://europepmc.org/article/PMC/PMC8163497
https://lup.lub.lu.se/record/fb917ef9-82a4-4ca2-a8b0-2bf232ab2865
https://pubmed.ncbi.nlm.nih.gov/33206936/
https://portal.research.lu.se/en/publications/genomic-and-transcriptomic-correlates-of-richters-transformation-
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/321418
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/326877 -
12
Authors: et al.
Contributors: et al.
Source: Annals of Hematology. 100:189-196
Subject Terms: Adult, Male, High-dose regimen, Transplantation Conditioning, Lymphoma, Antineoplastic Agents, Autologous stem cell transplantation, Transplantation, Autologous, Peripheral / diagnosis, Transplantation Conditioning / methods, Dose-Response Relationship, Hematopoietic Stem Cell Transplantation / methods, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Autologous / methods, Antineoplastic Combined Chemotherapy Protocols, Republic of Korea, Cytarabine / administration & dosage, Humans, Prospective Studies, T-cell lymphomas, Antineoplastic Combined Chemotherapy Protocols / administration & dosage, Antineoplastic Agents, Alkylating, Busulfan, Melphalan, Republic of Korea / epidemiology, Aged, Etoposide, Transplantation, Dose-Response Relationship, Drug, Phytogenic / administration & dosage, Cytarabine, Hematopoietic Stem Cell Transplantation, Lymphoma, T-Cell, Peripheral, Busulfan / administration & dosage, Middle Aged, T-Cell, Peripheral / drug therapy, Antineoplastic Agents, Phytogenic, Alkylating / administration & dosage, 3. Good health, Peripheral / epidemiology, Etoposide / administration & dosage, Female, Drug, Melphalan / administration & dosage
Access URL: https://pubmed.ncbi.nlm.nih.gov/33205337
https://www.ncbi.nlm.nih.gov/pubmed/33205337
https://europepmc.org/article/MED/33205337
https://pubmed.ncbi.nlm.nih.gov/33205337/
https://snucm.elsevierpure.com/en/publications/busulfan-etoposide-cytarabine-and-melphalan-as-a-high-dose-regime
https://link.springer.com/article/10.1007/s00277-020-04309-7 -
13
Authors: et al.
Contributors: et al.
Source: The Lancet. 396:1090-1100
Subject Terms: Adult, Paclitaxel, Humanized / adverse effects, Antineoplastic Agents, Triple Negative Breast Neoplasms, Antibodies, Monoclonal, Humanized, Cyclophosphamide / administration & dosage, Antibodies, Albumins / administration & dosage, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Albumins, Monoclonal, Antineoplastic Combined Chemotherapy Protocols / adverse effects, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide / adverse effects, Humans, Paclitaxel / administration & dosage, Triple Negative Breast Neoplasms / drug therapy, Antineoplastic Combined Chemotherapy Protocols / administration & dosage, Cyclophosphamide, Antineoplastic Agents / adverse effects, Doxorubicin / administration & dosage, Middle Aged, Doxorubicin / adverse effects, Neoadjuvant Therapy, 3. Good health, [SDV] Life Sciences [q-bio], Antineoplastic Agents / administration & dosage, Doxorubicin, Humanized / administration & dosage, Female
Access URL: https://pubmed.ncbi.nlm.nih.gov/32966830
https://www.sciencedirect.com/science/article/pii/S014067362031953X
https://hal.archives-ouvertes.fr/hal-03046446
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31953-X/fulltext
https://ohsu.pure.elsevier.com/en/publications/neoadjuvant-atezolizumab-in-combination-with-sequential-nab-pacli
https://europepmc.org/article/MED/32966830
https://pubmed.ncbi.nlm.nih.gov/32966830/ -
14
Authors: et al.
Contributors: et al.
Source: British Journal of Haematology, 193, 1, pp. 52-62
British journal of haematology, Vol. 193, no. 1, p. 52-62 (2021)
British Journal of HaematologySubject Terms: GUIDELINES, THERAPY, Cyclophosphamide/administration & dosage, Congenital Abnormalities/epidemiology, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Agents, Immunological, 0302 clinical medicine, Lymphoma, Large B-Cell, Diffuse/complications, Pregnancy, Antineoplastic Combined Chemotherapy Protocols, Vincristine/administration & dosage, International Network on Cancer Infertility Pregnancy (INCIP), Antineoplastic Agents, Immunological/therapeutic use, Medical Oncology - Radboud University Medical Center, 1102 Cardiorespiratory Medicine and Haematology, Fetal Growth Retardation/chemically induced, Fetal Growth Retardation, Stillbirth/epidemiology, non-Hodgkin lymphoma, Incidence, Lymphoma, Non-Hodgkin, Pregnancy Outcome, WOMEN, Hematology, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Stillbirth, Progression-Free Survival, 3. Good health, Vincristine, R-CHOP, Antibodies, Monoclonal, Murine-Derived/therapeutic use, Premature Birth, Female, pregnancy, Lymphoma, Large B-Cell, Diffuse, Rituximab, 3201 Cardiovascular medicine and haematology, Life Sciences & Biomedicine, Prednisolone/administration & dosage, Adult, Lymphoma, Non-Hodgkin/diagnosis, Adolescent, Prednisolone, Immunology, Radboudumc 17: Women's cancers RIHS: Radboud Institute for Health Sciences, diffuse large B-cell lymphoma, Gestational Age, Pregnancy Outcome/epidemiology, Congenital Abnormalities, 03 medical and health sciences, Rituximab/therapeutic use, MANAGEMENT, Pregnancy Complications/chemically induced, Humans, Cyclophosphamide, Retrospective Studies, Science & Technology, Doxorubicin/administration & dosage, Infant, Newborn, maternal outcome, Pregnancy Complications, Infertility/chemically induced, Doxorubicin, Infertility, incidence, Premature Birth/chemically induced
Access URL: https://lirias.kuleuven.be/bitstream/123456789/660499/2/NHL_INCIP_manuscript_v2.docx
https://pubmed.ncbi.nlm.nih.gov/32945547
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/232066
https://doi.org/10.1111/bjh.17103
https://pubmed.ncbi.nlm.nih.gov/32945547/
https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/covidwho-1227387
https://www.ncbi.nlm.nih.gov/pubmed/32945547
https://www.narcis.nl/publication/RecordID/oai%3Arepository.ubn.ru.nl%3A2066%2F232066
https://onlinelibrary.wiley.com/doi/10.1111/bjh.17103
https://pure.amsterdamumc.nl/en/publications/02dc75ee-cb28-4871-8978-0db625ba3938
https://doi.org/10.1111/bjh.17103
https://lirias.kuleuven.be/handle/123456789/660499
https://doi.org/10.1111/bjh.17103
https://hdl.handle.net/2066/232066
https://repository.ubn.ru.nl//bitstream/handle/2066/232066/232066.pdf
https://hdl.handle.net/2078.1/261615
https://biblio.vub.ac.be/vubir/(b10dd193-2eb1-4bf5-9bc7-369fe4b66f93).html -
15
Authors: et al.
Contributors: et al.
Source: The Lancet Oncology. 21:1045-1056
Subject Terms: Adult, Male, 0301 basic medicine, Leucovorin, Stomach Neoplasms / drug therapy, Adenocarcinoma, Oxaliplatin / administration & dosage, 03 medical and health sciences, 0302 clinical medicine, Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols / adverse effects, Antineoplastic Combined Chemotherapy Protocols, Humans, Tegafur / administration & dosage, Antineoplastic Combined Chemotherapy Protocols / administration & dosage, Oxaliplatin / adverse effects, Oxonic Acid / adverse effects, Aged, Tegafur, Leucovorin / administration & dosage, Leucovorin / adverse effects, Tegafur / adverse effects, Middle Aged, 3. Good health, Oxaliplatin, Drug Combinations, Oxonic Acid, Adenocarcinoma / drug therapy, Cisplatin / adverse effects, Female, Cisplatin, Cisplatin / administration & dosage, Oxonic Acid / administration & dosage
Access URL: https://pubmed.ncbi.nlm.nih.gov/32682457
http://www.sciencedirect.com/science/article/pii/S1470204520303156
https://s-space.snu.ac.kr/handle/10371/173205
https://koreauniv.pure.elsevier.com/en/publications/s-1-plus-leucovorin-and-oxaliplatin-versus-s-1-plus-cisplatin-as-
https://www.ncbi.nlm.nih.gov/pubmed/32682457
https://yonsei.pure.elsevier.com/en/publications/s-1-plus-leucovorin-and-oxaliplatin-versus-s-1-plus-cisplatin-as-
https://pubmed.ncbi.nlm.nih.gov/32682457/ -
16
Authors: et al.
Contributors: et al.
Source: European Journal of Cancer. 135:31-38
Subject Terms: Male, Time Factors, Skin Neoplasms, Imidazoles / administration & dosage, Mutation, Oximes / administration & dosage, Melanoma / pathology, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols / adverse effects, Oximes / adverse effects, Antineoplastic Combined Chemotherapy Protocols, Oximes, 80 and over, Tumor / genetics, Melanoma, Skin Neoplasms / genetics, Aged, 80 and over, Dabrafenib, Imidazoles, Protein Kinase Inhibitors / pharmacokinetics, Middle Aged, Proto-Oncogene Proteins B-raf / genetics, Progression-Free Survival, 3. Good health, Pyrimidinones / administration & dosage, Oximes / pharmacokinetics, Pyrimidinones / adverse effects, Female, Pyridones / administration & dosage, Adult, Proto-Oncogene Proteins B-raf, Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics, Asia, Melanoma / drug therapy, Pyridones, Imidazoles / pharmacokinetics, Skin Neoplasms / drug therapy, Pyrimidinones, Pyridones / adverse effects, Melanoma / mortality, BRAF, 03 medical and health sciences, Trametinib, Biomarkers, Tumor, Humans, Antineoplastic Combined Chemotherapy Protocols / administration & dosage, Protein Kinase Inhibitors, Protein Kinase Inhibitors / adverse effects, Aged, Skin Neoplasms / pathology, Chinese, Imidazoles / adverse effects, Protein Kinase Inhibitors / administration & dosage, Skin Neoplasms / mortality, Pyrimidinones / pharmacokinetics, Melanoma / genetics, Biomarkers, Pyridones / pharmacokinetics
Access URL: https://pubmed.ncbi.nlm.nih.gov/32534242
https://pubmed.ncbi.nlm.nih.gov/32534242/
https://snucm.elsevierpure.com/en/publications/open-label-phase-iia-study-of-dabrafenib-plus-trametinib-in-east-
https://www.sciencedirect.com/science/article/pii/S0959804920302495
https://www.ncbi.nlm.nih.gov/pubmed/32534242 -
17
Authors: et al.
Contributors: et al.
Source: European Journal of Cancer. 133:56-65
Subject Terms: Amenorrhea / epidemiology, Premature / drug effects, Primary Ovarian Insufficiency / prevention & control, Menopause, Premature, Menstruation / drug effects, Ovarian Neoplasms / drug therapy, Primary Ovarian Insufficiency / epidemiology, Gonadotropin releasing hormone agonist, Gonadotropin-Releasing Hormone, Amenorrhea / prevention & control, Female / therapeutic use, 0302 clinical medicine, Pregnancy, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Bleomycin / administration & dosage, Amenorrhea, Republic of Korea / epidemiology, Etoposide, Ovarian Neoplasms, Fertility Preservation / methods, Fertility Preservation, Amenorrhea / chemically induced, Neoplasms, Germ Cell and Embryonal, Ovarian Neoplasms / epidemiology, Menstruation, 3. Good health, Treatment Outcome, Bleomycin / adverse effects, Cisplatin / adverse effects, Germ Cell and Embryonal / epidemiology, Germ Cell and Embryonal / drug therapy, Female, Menopause, Gonadotropin-Releasing Hormone / agonists, Cisplatin / administration & dosage, Infertility, Female, Ovary / drug effects, Adult, Adolescent, Ovarian insufficiency, Female / prevention & control, Female / chemically induced, Fertility Agents, Ovarian germ cell cancer, Young Adult, Bleomycin, 03 medical and health sciences, Antineoplastic Combined Chemotherapy Protocols / adverse effects, Chemotherapy, Humans, Etoposide / adverse effects, Female / epidemiology, Retrospective Studies, Ovary, Fertility Agents, Female, Antineoplastic Combined Chemotherapy Protocols / administration & dosage, Primary Ovarian Insufficiency / chemically induced, Infertility, Etoposide / administration & dosage, Feasibility Studies, Cisplatin
Access URL: https://pubmed.ncbi.nlm.nih.gov/32442924
https://khu.elsevierpure.com/en/publications/feasibility-and-efficacy-of-gonadotropin-releasing-hormone-agonis
https://www.sciencedirect.com/science/article/abs/pii/S0959804920302094
https://pubmed.ncbi.nlm.nih.gov/32442924/
https://www.ncbi.nlm.nih.gov/pubmed/32442924
http://www.ncbi.nlm.nih.gov/pubmed/32442924 -
18
Authors: et al.
Contributors: et al.
Source: American Journal of Hematology, 95, 7, pp. 749-758
Subject Terms: Male, 0302 clinical medicine, Radboudumc 2: Cancer development and immune defence RIMLS: Radboud Institute for Molecular Life Sciences, Antineoplastic Combined Chemotherapy Protocols, inglese, Mitoxantrone / adverse effects, Human health sciences, Haematology - Radboud University Medical Center, Etoposide, Leukemia, Myeloid, Acute / therapy, Daunorubicin / administration & dosage, Age Factors, Cytarabine, Hematopoietic Stem Cell Transplantation, Idarubicin / adverse effects, Hematology, Induction Chemotherapy, Middle Aged, Allografts, 3. Good health, Leukemia, Myeloid, Acute, Cytarabine / administration & dosage, Female, Adult, Cytarabine / adverse effects, Adolescent, Idarubicin / administration & dosage, acute myeloid leukemia, anthracycline, Sciences de la santé humaine, Daunorubicin / adverse effects, Article, 03 medical and health sciences, Mitoxantrone / administration & dosage, Radboudumc 16: Vascular damage RIHS: Radboud Institute for Health Sciences, Humans, Etoposide / adverse effects, Antineoplastic Combined Chemotherapy Protocols / administration & dosage, HLA matching, Daunorubicin, Tumorimmunology - Radboud University Medical Center, HLA matching, anthracycline, acute myeloid leukemia, Leukemia, Myeloid, Acute / mortality, Etoposide / administration & dosage, Radboudumc 5: Inflammatory diseases RIHS: Radboud Institute for Health Sciences, Human Genetics - Radboud University Medical Center, Mitoxantrone, Idarubicin, Hématologie, Follow-Up Studies
File Description: application/pdf
Access URL: https://orbi.uliege.be/bitstream/2268/250603/1/baron2020.pdf
https://pubmed.ncbi.nlm.nih.gov/32233095
https://www.bib.irb.hr/1274620
https://doi.org/10.1002/ajh.25795
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/220443
https://doi.org/10.1002/ajh.25795
https://orbi.uliege.be/handle/2268/250603
https://doi.org/10.1002/ajh.25795
https://www.narcis.nl/publication/RecordID/oai%3Arepository.ubn.ru.nl%3A2066%2F220443
https://doi.org/10.1002%2Fajh.25795
https://moh-it.pure.elsevier.com/en/publications/impact-of-the-type-of-anthracycline-and-of-stem-cell-transplantat
https://orbi.uliege.be/handle/2268/250603
https://onlinelibrary.wiley.com/doi/10.1002/ajh.25795
https://www.ncbi.nlm.nih.gov/pubmed/32233095
https://hdl.handle.net/1887/3185054
https://hdl.handle.net/2066/220443
https://repository.ubn.ru.nl//bitstream/handle/2066/220443/220443.pdf
https://hdl.handle.net/2268/250603
https://doi.org/10.1002/ajh.25795
https://urn.nsk.hr/urn:nbn:hr:105:157213
https://doi.org/10.1002/ajh.25795 -
19
Authors: et al.
Contributors: et al.
Source: Annals of Hematology. 99:255-264
Subject Terms: Adult, Male, Vascular Endothelial Growth Factor A, Cytarabine / adverse effects, Time Factors, Methylprednisolone, Disease-Free Survival, Oxaliplatin / administration & dosage, Hodgkin Disease* / mortality, 03 medical and health sciences, Tumor Necrosis Factor-alpha / blood, 0302 clinical medicine, Recurrence, Antineoplastic Combined Chemotherapy Protocols / adverse effects, Antineoplastic Combined Chemotherapy Protocols, Humans, Etoposide / adverse effects, Vascular Endothelial Growth Factor A / blood, Antineoplastic Combined Chemotherapy Protocols / administration & dosage, Oxaliplatin / adverse effects, Aged, Etoposide, Methylprednisolone / administration & dosage, Hodgkin's lymphoma, Methylprednisolone / adverse effects, Tumor Necrosis Factor-alpha, Hodgkin Disease* / blood, Cytarabine, Hodgkin Disease* / drug therapy, Middle Aged, Hodgkin Disease, Neoplasm Proteins / blood, Neoplasm Proteins, 3. Good health, Oxaliplatin, Survival Rate, C-Reactive Protein / metabolism, Cytarabine / administration & dosage, C-Reactive Protein, Etoposide / administration & dosage, Female
Access URL: https://pubmed.ncbi.nlm.nih.gov/31897676
https://link.springer.com/article/10.1007/s00277-019-03891-9
https://pubmed.ncbi.nlm.nih.gov/31897676/
https://www.ncbi.nlm.nih.gov/pubmed/31897676
https://hanyang.elsevierpure.com/en/publications/a-phase-ii-study-of-etoposide-methylprednisolone-high-dose-cytara
https://snucm.elsevierpure.com/en/publications/a-phase-ii-study-of-etoposide-methylprednisolone-high-dose-cytara -
20
Source: DeLLphi-304 Investigators 2025, 'Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy', The New England Journal of Medicine, vol. 393, no. 4, pp. 349-361. https://doi.org/10.1056/NEJMoa2502099
Subject Terms: Adult, Aged, 80 and over, Female, Humans, Male, Middle Aged, Anthracyclines, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Lung Neoplasms/complications, Progression-Free Survival, Small Cell Lung Carcinoma/complications, Topotecan/administration & dosage, Antibodies, Bispecific/administration & dosage, Antineoplastic Agents, Immunological/administration & dosage, Dyspnea/diagnosis, Cough/diagnosis, Severity of Illness Index, Disease Progression, Treatment Outcome, Young Adult, Carbolines, Heterocyclic Compounds, 4 or More Rings
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science